Loomis Sayles & CO L P Xencor Inc Transaction History

Loomis Sayles & CO L P

  • $76.2 Billion
  • Q3 2024

A detailed history of Loomis Sayles & CO L P transactions in Xencor Inc stock. As of the latest transaction made, Loomis Sayles & CO L P holds 900,266 shares of XNCR stock, worth $18.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
900,266
Previous 921,184 2.27%
Holding current value
$18.6 Million
Previous $17.4 Million 3.82%
% of portfolio
0.02%
Previous 0.02%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$15.7 - $21.65 $328,412 - $452,874
-20,918 Reduced 2.27%
900,266 $18.1 Million
Q2 2024

Aug 13, 2024
SELL
$18.21 - $24.5 $666,977 - $897,361
-36,627 Reduced 3.82%
921,184 $17.4 Million
Q1 2024

May 14, 2024
SELL
$18.65 - $26.52 $567,575 - $807,083
-30,433 Reduced 3.08%
957,811 $21.2 Million
Q4 2023

Feb 13, 2024
SELL
$16.53 - $21.42 $8.57 Million - $11.1 Million
-518,308 Reduced 34.4%
988,244 $21 Million
Q3 2023

Nov 09, 2023
SELL
$20.08 - $25.39 $8.07 Million - $10.2 Million
-401,806 Reduced 21.06%
1,506,552 $30.4 Million
Q2 2023

Aug 11, 2023
SELL
$24.77 - $29.9 $973,733 - $1.18 Million
-39,311 Reduced 2.02%
1,908,358 $47.7 Million
Q1 2023

May 11, 2023
BUY
$25.95 - $36.95 $109,457 - $155,855
4,218 Added 0.22%
1,947,669 $54.3 Million
Q4 2022

Feb 10, 2023
BUY
$24.79 - $30.86 $3.87 Million - $4.82 Million
156,098 Added 8.73%
1,943,451 $50.6 Million
Q3 2022

Nov 14, 2022
SELL
$24.62 - $32.44 $489,002 - $644,323
-19,862 Reduced 1.1%
1,787,353 $46.4 Million
Q2 2022

Aug 05, 2022
SELL
$19.74 - $29.01 $214,021 - $314,526
-10,842 Reduced 0.6%
1,807,215 $49.5 Million
Q1 2022

May 13, 2022
BUY
$26.68 - $41.63 $3.04 Million - $4.74 Million
113,818 Added 6.68%
1,818,057 $48.5 Million
Q4 2021

Feb 14, 2022
BUY
$33.67 - $43.44 $4.25 Million - $5.49 Million
126,279 Added 8.0%
1,704,239 $68.4 Million
Q3 2021

Nov 12, 2021
BUY
$30.65 - $35.68 $12.3 Million - $14.3 Million
402,062 Added 34.19%
1,577,960 $51.5 Million
Q2 2021

Aug 13, 2021
BUY
$34.33 - $44.68 $69,827 - $90,879
2,034 Added 0.17%
1,175,898 $40.6 Million
Q1 2021

May 17, 2021
BUY
$40.81 - $53.88 $2.05 Million - $2.71 Million
50,223 Added 4.47%
1,173,864 $50.5 Million
Q4 2020

Feb 12, 2021
BUY
$36.63 - $47.63 $13.1 Million - $17.1 Million
358,119 Added 46.78%
1,123,641 $49 Million
Q3 2020

Nov 12, 2020
BUY
$30.09 - $43.02 $3.72 Million - $5.31 Million
123,546 Added 19.24%
765,522 $29.7 Million
Q2 2020

Aug 14, 2020
BUY
$27.76 - $33.42 $1.55 Million - $1.87 Million
55,871 Added 9.53%
641,976 $20.8 Million
Q1 2020

May 15, 2020
BUY
$20.69 - $37.79 $74,649 - $136,346
3,608 Added 0.62%
586,105 $17.5 Million
Q4 2019

Feb 14, 2020
SELL
$32.75 - $41.43 $61,406 - $77,681
-1,875 Reduced 0.32%
582,497 $20 Million
Q3 2019

Nov 13, 2019
BUY
$33.73 - $46.27 $2.23 Million - $3.06 Million
66,237 Added 12.78%
584,372 $19.7 Million
Q2 2019

Aug 14, 2019
BUY
$29.6 - $40.93 $2.84 Million - $3.92 Million
95,810 Added 22.69%
518,135 $21.2 Million
Q1 2019

May 15, 2019
SELL
$27.85 - $38.09 $354,836 - $485,304
-12,741 Reduced 2.93%
422,325 $13.1 Million
Q4 2018

Feb 14, 2019
BUY
$32.39 - $42.05 $241,564 - $313,608
7,458 Added 1.74%
435,066 $15.7 Million
Q3 2018

Nov 13, 2018
BUY
$35.69 - $47.65 $2 Million - $2.68 Million
56,139 Added 15.11%
427,608 $16.7 Million
Q2 2018

Aug 14, 2018
BUY
$28.41 - $42.41 $10.6 Million - $15.8 Million
371,469 New
371,469 $13.7 Million

Others Institutions Holding XNCR

# of Institutions
215
Shares Held
71.5M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.23B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email